Emerging
Jun 18, 20261
61%
FDA Advisory Panel Unanimously Backs Moderna's mRNA Flu Vaccine
The FDA's advisory panel unanimously recommended approval of Moderna's mFlusiva, the first mRNA-based flu vaccine, representing a major expansion of mRNA technology beyond COVID-19. The vaccine showed a 27 percent reduction in flu cases in trials and could enable faster vaccine manufacturing if flu viruses mutate unexpectedly.
Quick Facts
Who
Moderna
What
FDA advisory panel voted unanimously to recommend approval of mFlusiva flu vaccine
When
June 2026
Where
United States
- FDA advisory panel voted unanimously to recommend approval of mFlusiva flu vaccine
- Moderna sought full approval for ages 50-64 and authorization for ages 65+ with ongoing testing
- Clinical trial showed 27% reduction in flu cases
- Vaccine demonstrated strong immune response in older adults versus high-dose alternatives
- Moderna
Federal health advisors have recommended approval of Moderna's mFlusiva, the first flu vaccine using messenger RNA (mRNA) technology, marking a significant step toward expanding mRNA-based vaccines beyond COVID-19 prevention. The FDA's independent advisory committee voted unanimously that the vaccine's benefits appear to outweigh any risks for adults aged 50 and older, with the FDA expected to make a final decision in early August 2026.
Moderna is seeking full approval for adults aged 50 to 64, along with authorization for those 65 and older while conducting additional testing. In clinical trials, the mRNA vaccine reduced flu cases by approximately 27 percent compared to standard flu vaccines in a study of 40,000 people aged 50 and older. In a smaller study of adults 65 and over, Moderna's injection generated a stronger protective immune response compared to high-dose flu vaccines already recommended for that age group. The company plans to conduct a follow-up study with 400,000 adults aged 65 and older if authorized, with half receiving the mRNA version and half receiving current flu vaccines for older adults.
The potential advantage of mRNA flu vaccines lies in their rapid manufacturing capability. Unlike traditional flu vaccines where vaccine strains must be selected in February for autumn rollout, mRNA technology could enable faster vaccine updates if the circulating flu virus mutates significantly after the formula is finalized. "Having this technology available positions us better to be prepared for emerging strains in the future," said Dr. Flor Muñoz-Rivas, an FDA advisor from Texas Children's Hospital. Dr. Rituparna Das of Moderna noted that the company's ability to quickly manufacture mRNA vaccines matching recent flu strains could prevent thousands of hospitalizations in older Americans.
Tens of thousands of Americans die from influenza annually, with older adults among the most vulnerable populations. Several flu vaccines are already available in the United States, including three specifically recommended for people 65 and older. The mRNA technology, which won the Nobel Prize, manufactures faster than other vaccine types, potentially addressing a critical gap when flu viruses mutate unexpectedly and new dose formulations must be developed quickly.
Why This Matters
This approval represents a critical expansion of mRNA vaccine technology beyond pandemic response, offering healthcare systems a faster pathway to combat seasonal flu mutations. For older adults aged 50 and above—the most vulnerable population to severe influenza—mFlusiva could reduce hospitalizations and deaths significantly. The rapid manufacturing advantage of mRNA vaccines positions public health to respond more effectively when flu viruses evolve unexpectedly, potentially preventing thousands of deaths annually.